A Phase IIIB Open Label Study To Optimize The Single Bolus Dose Of Dalteparin Sodium For The Prevention Of Clotting Within The Extracorporeal System During Hemodialysis Procedures For Subjects With Chronic Renal Insufficiency: The Parrot Study

Trial Profile

A Phase IIIB Open Label Study To Optimize The Single Bolus Dose Of Dalteparin Sodium For The Prevention Of Clotting Within The Extracorporeal System During Hemodialysis Procedures For Subjects With Chronic Renal Insufficiency: The Parrot Study

Completed
Phase of Trial: Phase III

Latest Information Update: 16 Mar 2017

At a glance

  • Drugs Dalteparin sodium (Primary)
  • Indications Acute coronary syndromes; Deep vein thrombosis; Thromboembolism
  • Focus Registrational; Therapeutic Use
  • Acronyms Parrot
  • Sponsors Pfizer
  • Most Recent Events

    • 04 Apr 2016 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 12 Feb 2016 Status changed from recruiting to active, no longer recruiting, according to ClinicalTrials.gov record.
    • 05 May 2015 Planned End Date changed from 1 Jun 2015 to 1 Jul 2016 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top